Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Cyclacel Pharmaceuticals Q4 EPS $(6.23) Misses $(5.89) Estimate, Sales $31.00K

Author: Happy Mohamed | March 19, 2024 04:06pm
Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(6.23) per share which missed the analyst consensus estimate of $(5.89) by 5.77 percent. This is a 30.78 percent increase over losses of $(9.00) per share from the same period last year. The company reported $31.00 thousand in sales this quarter.

Posted In: CYCC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist